Evoke Pharma Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis

Second Phase 2 Trial Demonstrates Effectiveness of Intranasal Metoclopramide Spray

SOLANA BEACH, Calif., June 24, 2015 -- Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that previously disclosed results from its Phase 2b clinical trial evaluating EVK-001, its patented intranasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women, have been published in the July issue of Clinical Gastroenterology and Hepatology, a leading peer-reviewed journal published by the American Gastroenterological Association (AGA).

Published: 24 June 2015

Written by Editor

Nasdaq Up on News Project Update

Celator® Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia

CPX-351 demonstrates a 43.2% relative improvement in induction response rate
Conference call today at 8:30am Eastern Time to discuss the results

EWING, N.J., June 24, 2015 -- Celator Pharmaceuticals, Inc. (CPXX) today announced final induction response rate results (complete remission plus complete remission with incomplete hematologic recovery, or CR+CRi) in the Phase 3 study comparing CPX-351 (cytarabine:daunorubicin) liposome injection to the standard of care regimen, referred to as 7+3 (conventional cytarabine and daunorubicin treatment), in patients with untreated high-risk (secondary) acute myeloid leukemia (AML). The results showed that CPX-351 produced a relative improvement in induction response rate of 43.2% (47.7% for CPX-351 vs. 33.3% for the 7+3 regimen).

Published: 24 June 2015

Written by Editor

Nasdaq Up on News Project Update

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

CALGARY , June 22, 2015 - Resverlogix Corp. (RVX.TO) today announced that following recent meetings with various European regulatory bodies, the first confirmation for our Phase 3 clinical plan has officially been received. A further regulatory and protocol design update will be provided to the market post the approval of additional regulatory bodies and the launch of our planned Phase 3 clinical trial entitled BETonMACE.

"This represents a momentous step forward in the clinical development of RVX-208," stated Donald McCaffrey , president and chief executive officer of Resverlogix. "With this important regulatory confirmation now complete, we expect to launch the upcoming BETonMACE Phase 3 clinical trial this fall. The primary endpoint of the BETonMACE trial is designed to show a relative risk reduction (RRR) of Major Adverse Cardiac Events (MACE) in high-risk cardiovascular and diabetes mellitus (DM) patients, as we have seen in previous Phase 2 clinical trials with RVX-208," further stated Mr. McCaffrey.

Published: 22 June 2015

Written by Editor

Up on News Project Update TSXV

Epizyme Announces Additional Positive Data from Ongoing Phase 1 Study of Tazemetostat (EPZ-6438) in Relapsed or Refractory Non-Hodgkin Lymphoma

Objective responses seen in nine of 15 evaluable relapsed non-Hodgkin lymphoma (NHL) patients; five responders remain on study
First treated patient with an EZH2 mutant tumor achieved partial response and remains on study
Phase 2 NHL trial now enrolling patients; plans for expanded phase 2 program, including combination studies announced
Company to hold conference call and webcast on Monday, June 22, 2015, at 8:00 a.m. ET

LUGANO, Switzerland---- Epizyme, Inc. (EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today reported results from the ongoing phase 1 trial of tazemetostat (EPZ-6438), a first-in-class EZH2 inhibitor, showing meaningful clinical activity when used as an oral monotherapy in patients with advanced B-cell non-Hodgkin lymphomas (NHL) and solid tumors.

Published: 22 June 2015

Written by Editor

Nasdaq Up on News Project Update

BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study

- 50% Increase in mean annualized growth velocity in 15 ug/kg/daily dose group
- BMN 111 was well tolerated across all three dose cohorts
- Phase 2 findings support program advancement of 15ug/kg/daily dose into pivotal registration discussions with health authorities
- Investor conference call to be held today, June 17, 2015 at 1:30pm PT/(4:30pm ET)

SAN RAFAEL, Calif., June 17, 2015 -- BioMarin Pharmaceutical Inc. (BMRN) today announced positive results of a Phase 2 proof-of-concept and dose finding study of BMN 111 (vosoritide), an analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia. Achondroplasia is the most common form of human dwarfism. Vosoritide has Orphan designation in both the United States and Europe.

Published: 18 June 2015

Written by Editor

Nasdaq Up on News Project Update

Page 130 of 246

Evoke Pharma Inc ( EVOK )

Evoke Pharma Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis

Celator Pharmaceuticals Inc ( CPXX )

Celator® Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia

Resverlogix Corp ( RVX )

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

Epizyme Inc ( EPZM )

Epizyme Announces Additional Positive Data from Ongoing Phase 1 Study of Tazemetostat (EPZ-6438) in Relapsed or Refractory Non-Hodgkin Lymphoma

BioMarin Pharmaceutical Inc ( BMRN )

BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study